The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent.

A clot-busting drug recently approved to treat acute ischemic strokes (AIS) that can be delivered quickly works as well as a ...

Among stroke survivors, the risk of developing dementia after stroke is significantly high, highlighting the need for targeted prevention strategies.

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

Coinciding with the FDA’s clearance for the catheter, Perfuze has also completed a €22m ($24m) financing round.

Two randomized trials in China find that intra-arterial thrombolysis with urokinase or tenecteplase does not significantly ...

(HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

Hyderabad: Apollo Hospitals organised the STAT-2025 Conference on Stroke Thrombolysis and Thrombectomy with leading ...

The study, published March 12 in JAMA Network Open, compared the newly approved tenecteplase in a single quick injection to alteplase, the stroke treatment that has been used for decades and requires ...

Perfuze, an Ireland-based developer of catheter-based aspiration technology for the treatment of acute ischemic stroke, ...

Stroke, (paralysis) or a brain attack is a disabling brain disorder that affects more than 20 million people across the world ...

The following is a summary of “Reducing time delays and enhancing reperfusion eligibility related to stroke suspicion by the ...